Novel heterocycles useful in the treatment of benign prostatic hyperplasia

What is claimed is a compound of Formula I

• 72
• wherein:
• R1 is hydrogen, halogen, C1-5alkoxy, hydroxyl, or C1-6alkyl;
• R2 is C1-6alkyl, substituted C1-6alkyl
• where the alkyl substituents are one or more halogens, phenyl, substituted phenyl
• where the phenyl substituents are independently selected from one or more of the group consisting of C1-5alkyl, C1-5alkoxy, and trihaloC1-5alkyl), phenylC1-5alkyl, or substituted phenylC1-5alkyl
• where the phenyl substituents are independently selected from one or more of the group consisting of C1-5alkyl, halogen, C1-5alkoxy, and trihaloC1-5alkyl;
• R3 is hydrogen, C1-5alkoxycarbonyl, C1-5alkyl, hydroxyC1-5alkyl, formyl, acetyl, amido, or oxygen
• where if R3 is oxygen the hashed line is solid is taken together with the other solid line to represent a double bond, and if R3 is not oxygen, the hashed line represents a single bond affixed to a hydrogen;
• A is selected from the group consisting of
• 73
• where the points of attachment are depicted by the hashed bonds,
• where one point of attachment is bonded to the methylene adjacent to the depicted piperazine and the second point of attachment is bonded to the other methylene;
• R4 is hydrogen or C1-5alkyl;
• B is hydrogen or oxygen,
• where if B is oxygen the hashed line is solid and is taken together with the other solid line to represent a double bond, and if B is hydrogen the hashed line represents a single bond affixed to a hydrogen;
• Z is —(CH2)n— where n is 1-5, —CH2—CR5R6—CH2—, —CHR5R6CH—
• where R5 and R6 are hydrogen, C1-5alkyl or taken together to form a C3-8cycloalkane, or
• 74
• where ring X is an aromatic ring of 6 members;
• or pharmaceutically acceptable salts thereof.